150 related articles for article (PubMed ID: 28130214)
1. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Oliva L; Orfanelli U; Resnati M; Raimondi A; Orsi A; Milan E; Palladini G; Milani P; Cerruti F; Cascio P; Casarini S; Rognoni P; Touvier T; Marcatti M; Ciceri F; Mangiacavalli S; Corso A; Merlini G; Cenci S
Blood; 2017 Apr; 129(15):2132-2142. PubMed ID: 28130214
[TBL] [Abstract][Full Text] [Related]
2. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion.
Rius B; Mesgarzadeh JS; Romine IC; Paxman RJ; Kelly JW; Wiseman RL
Blood Adv; 2021 Feb; 5(4):1037-1049. PubMed ID: 33599742
[TBL] [Abstract][Full Text] [Related]
4. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.
Paiva B; Martinez-Lopez J; Corchete LA; Sanchez-Vega B; Rapado I; Puig N; Barrio S; Sanchez ML; Alignani D; Lasa M; García de Coca A; Pardal E; Oriol A; Garcia ME; Escalante F; González-López TJ; Palomera L; Alonso J; Prosper F; Orfao A; Vidriales MB; Mateos MV; Lahuerta JJ; Gutierrez NC; San Miguel JF
Blood; 2016 Jun; 127(24):3035-9. PubMed ID: 27069257
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
[TBL] [Abstract][Full Text] [Related]
8. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.
Fraser CS; Spetz JKE; Qin X; Presser A; Choiniere J; Li C; Yu S; Blevins F; Hata AN; Miller JW; Bradshaw GA; Kalocsay M; Sanchorawala V; Sarosiek S; Sarosiek KA
Nat Commun; 2022 Oct; 13(1):5789. PubMed ID: 36184661
[TBL] [Abstract][Full Text] [Related]
9. Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.
Zhou P; Teruya-Feldstein J; Lu P; Fleisher M; Olshen A; Comenzo RL
Blood; 2008 Jan; 111(2):549-57. PubMed ID: 17982021
[TBL] [Abstract][Full Text] [Related]
10. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
11. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
12. Analysis of plasma cell clonality in localized AL amyloidosis.
Setoguchi M; Hoshii Y; Kawano H; Ishihara T
Amyloid; 2000 Mar; 7(1):41-5. PubMed ID: 10842704
[TBL] [Abstract][Full Text] [Related]
13. The proteasome in terminal plasma cell differentiation.
Cenci S
Semin Hematol; 2012 Jul; 49(3):215-22. PubMed ID: 22726544
[TBL] [Abstract][Full Text] [Related]
14. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.
Lavatelli F; Imperlini E; Orrù S; Rognoni P; Sarnataro D; Palladini G; Malpasso G; Soriano ME; Di Fonzo A; Valentini V; Gnecchi M; Perlini S; Salvatore F; Merlini G
FASEB J; 2015 Nov; 29(11):4614-28. PubMed ID: 26220173
[TBL] [Abstract][Full Text] [Related]
15. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
Nevone A; Girelli M; Mangiacavalli S; Paiva B; Milani P; Cascino P; Piscitelli M; Speranzini V; Cartia CS; Benvenuti P; Goicoechea I; Fazio F; Basset M; Foli A; Nanci M; Mazzini G; Caminito S; Sesta MA; Casarini S; Rognoni P; Lavatelli F; Petrucci MT; Olimpieri PP; Ricagno S; Arcaini L; Merlini G; Palladini G; Nuvolone M
Leukemia; 2022 Aug; 36(8):2076-2085. PubMed ID: 35610346
[TBL] [Abstract][Full Text] [Related]
16. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells.
Keeling J; Teng J; Herrera GA
Lab Invest; 2004 Oct; 84(10):1322-38. PubMed ID: 15286662
[TBL] [Abstract][Full Text] [Related]
17. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.
Zhou P; Hoffman J; Landau H; Hassoun H; Iyer L; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):49-58. PubMed ID: 22100494
[TBL] [Abstract][Full Text] [Related]
18. Future directions in the clinical management of amyloid light-chain amyloidosis.
Haider S; Ahmad N; Anaissie E; Driscoll JJ
Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
[TBL] [Abstract][Full Text] [Related]
19. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
Alameda D; Goicoechea I; Vicari M; Arriazu E; Nevone A; Rodriguez S; Lasa M; Puig N; Cedena MT; Alignani D; Garate S; Lara-Astiaso D; Vilas-Zornoza A; Sarvide S; Ocio EM; Lecumberri R; Garcia de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Perez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Fazio VM; Martinez-Lopez J; Lahuerta JJ; Mateos MV; Odero MD; Prosper F; Weiner A; Amit I; Nuvolone M; San Miguel JF; Paiva B
Blood; 2021 Oct; 138(17):1583-1589. PubMed ID: 34133718
[TBL] [Abstract][Full Text] [Related]
20. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]